MCID: PHR004
MIFTS: 44

Pharynx Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Pharynx Cancer

MalaCards integrated aliases for Pharynx Cancer:

Name: Pharynx Cancer 12 15 17
Pharyngeal Neoplasms 43 71
Pharyngeal Cancer 12 54
Malignant Neoplasm of Pharynx 71
Pharyngeal Carcinoma 71
Pharyngeal Neoplasm 12
Pharynx Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060119
MeSH 43 D010610
NCIt 49 C3325
SNOMED-CT 67 95001001
ICD10 32 C14.0
UMLS 71 C0031347 C0153405 C0747548

Summaries for Pharynx Cancer

Disease Ontology : 12 A gastrointestinal system cancer that is located in the pharynx.

MalaCards based summary : Pharynx Cancer, also known as pharyngeal neoplasms, is related to nasopharyngeal carcinoma and oral cancer. An important gene associated with Pharynx Cancer is FAM3D-AS1 (FAM3D Antisense RNA 1), and among its related pathways/superpathways are MicroRNAs in cancer and Parkinsons Disease Pathway. The drugs Ethanol and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include pharynx, thyroid and liver.

Related Diseases for Pharynx Cancer

Diseases in the Pharynx Cancer family:

Pharynx Carcinoma in Situ

Diseases related to Pharynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 198)
# Related Disease Score Top Affiliating Genes
1 nasopharyngeal carcinoma 32.2 MIR93 MIR9-1 MIR34C MIR324 MIR30A MIR29C
2 oral cancer 31.0 MIR21 GSTM3 ADH1C
3 oral squamous cell carcinoma 30.7 MIR9-1 MIR34C MIR29B1 MIR27A MIR21 MIR199A1
4 in situ carcinoma 30.7 MIR30A MIR17 MIR142
5 esophageal cancer 30.6 MIR93 MIR9-1 MIR30A MIR27A MIR21 MIR199A1
6 larynx cancer 30.5 MIR93 MIR34C MIR27A MIR21 MIR196A1 MIR17
7 oral cavity cancer 30.2 MIR93 MIR9-1 MIR324 MIR30A MIR29B1 MIR27A
8 cervical cancer 30.0 MIR93 MIR9-1 MIR34C MIR30A MIR29B1 MIR27A
9 squamous cell carcinoma, head and neck 29.9 MIR9-1 MIR324 MIR30A MIR29C MIR27A MIR21
10 pharynx squamous cell carcinoma 11.2
11 hypopharynx cancer 11.2
12 oropharynx cancer 11.2
13 thyroid gland anaplastic carcinoma 10.7 MIR34C MIR30A MIR17
14 pleural cancer 10.6 MIR29C MIR185 MIR17
15 leiomyoma, uterine 10.6 MIR30A MIR29C MIR27A MIR21
16 chromosomal deletion syndrome 10.6 MIR9-1 MIR185 MIR17 MIR142
17 ovarian cystadenocarcinoma 10.6 MIR30A MIR196A1 MIR17
18 esophagus adenocarcinoma 10.6 MIR21 MIR196A1 MIR145
19 intestinal benign neoplasm 10.6 MIR21 MIR199A1 MIR17 MIR142
20 aortic valve disease 2 10.6 MIR29B1 MIR21 MIR199A1 MIR17
21 intrinsic cardiomyopathy 10.6 MIR30A MIR21 MIR199A1 MIR142
22 heart conduction disease 10.6 MIR29B1 MIR21 MIR199A1 MIR142
23 pleural disease 10.6 MIR29C MIR185 MIR125A
24 bone cancer 10.6 MIR9-1 MIR27A MIR21 MIR199A1
25 thyroid gland papillary carcinoma 10.6 MIR9-1 MIR30A MIR199A1 MIR17 MIR125A
26 renal fibrosis 10.6 MIR29C MIR21 MIR199A1 MIR196A1
27 x-linked monogenic disease 10.6 MIR9-1 MIR27A MIR196A1 MIR142
28 pre-malignant neoplasm 10.6 MIR30A MIR17 MIR142
29 cervix carcinoma 10.6 MIR34C MIR27A MIR199A1 MIR142
30 muscle tissue disease 10.6 MIR9-1 MIR199A1 MIR196A1 MIR142
31 collagen disease 10.6 MIR30A MIR21 MIR142
32 melanoma, uveal 10.6 MIR93 MIR9-1 MIR29C MIR199A1 MIR142
33 inherited metabolic disorder 10.6 MIR9-1 MIR21 MIR199A1 MIR17 MIR142
34 contractures, pterygia, and variable skeletal fusions syndrome 1a 10.6 MIR9-1 MIR199A1 MIR196A1 MIR17
35 uveal disease 10.6 MIR9-1 MIR199A1 MIR142
36 autoimmune disease of musculoskeletal system 10.6 MIR30A MIR21 MIR196A1 MIR142 MIR125A
37 chromosomal disease 10.6 MIR9-1 MIR196A1 MIR185 MIR17 MIR142
38 rectum cancer 10.6 MIR21 MIR196A1 MIR17 MIR145 MIR125A
39 gastrointestinal system benign neoplasm 10.6 MIR21 MIR199A1 MIR196A1 MIR17 MIR142
40 gallbladder disease 10.6 MIR29C MIR199A1 MIR17 MIR145 MIR142
41 endocrine organ benign neoplasm 10.6 MIR21 MIR199A1 MIR196A1 MIR17 MIR142
42 ovary adenocarcinoma 10.6 MIR30A MIR29C MIR17
43 muscle cancer 10.6 MIR9-1 MIR199A1 MIR196A1
44 epithelioid cell melanoma 10.6 MIR93 MIR9-1
45 serous cystadenocarcinoma 10.6 MIR30A MIR199A1 MIR10B
46 non-alcoholic fatty liver disease 10.6 MIR30A MIR29C MIR27A MIR21 MIR17 MIR10B
47 pancreatitis, hereditary 10.6 MIR199A1 MIR125A MIR10B
48 bile duct cancer 10.6 MIR9-1 MIR199A1 MIR17 MIR125A
49 diffuse large b-cell lymphoma 10.6 MIR21 MIR199A1 MIR17 MIR145 MIR142
50 kidney cancer 10.6 MIR29C MIR27A MIR21 MIR199A1 MIR185 MIR17

Comorbidity relations with Pharynx Cancer via Phenotypic Disease Network (PDN):


Deficiency Anemia Larynx Cancer
Protein-Energy Malnutrition Swallowing Disorders

Graphical network of the top 20 diseases related to Pharynx Cancer:



Diseases related to Pharynx Cancer

Symptoms & Phenotypes for Pharynx Cancer

Drugs & Therapeutics for Pharynx Cancer

Drugs for Pharynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 3 64-17-5 702
2
Fluorouracil Approved Phase 3 51-21-8 3385
3
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
4
Hydroxyurea Approved Phase 3 127-07-1 3657
5 Anesthetics, Local Phase 3
6 Immunologic Factors Phase 3
7 Antimitotic Agents Phase 3
8 Immunosuppressive Agents Phase 3
9 Antimetabolites Phase 3
10
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
11
Celecoxib Approved, Investigational Phase 1, Phase 2 169590-42-5 2662
12
nivolumab Approved Phase 1, Phase 2 946414-94-4
13
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
14
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
15
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
16
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
17
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
18
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
19
Ifosfamide Approved Phase 2 3778-73-2 3690
20
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
21 Nigella Phase 2
22 Protein Kinase Inhibitors Phase 1, Phase 2
23 Mitogens Phase 1, Phase 2
24
Erlotinib Hydrochloride Phase 1, Phase 2 183319-69-9 176871
25 Antirheumatic Agents Phase 1, Phase 2
26 Analgesics Phase 1, Phase 2
27 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
28 Cyclooxygenase Inhibitors Phase 1, Phase 2
29 Analgesics, Non-Narcotic Phase 1, Phase 2
30 Anti-Inflammatory Agents Phase 1, Phase 2
31 Cyclooxygenase 2 Inhibitors Phase 1, Phase 2
32 Antibodies, Monoclonal Phase 1, Phase 2
33 Immunoglobulins Phase 1, Phase 2
34 Antibodies Phase 1, Phase 2
35 Albumin-Bound Paclitaxel Phase 2
36 Antiemetics Phase 2
37 Antineoplastic Agents, Immunological Phase 2
38 Anti-Bacterial Agents Phase 2
39 Alkylating Agents Phase 2
40
Isophosphamide mustard Phase 2 0
41 Antibiotics, Antitubercular Phase 2
42 Topoisomerase Inhibitors Phase 2
43
Liposomal doxorubicin Phase 2 31703
44 diuretics Phase 2
45
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
46
Bevacizumab Approved, Investigational Phase 1 216974-75-3
47
Etoposide Approved Phase 1 33419-42-0 36462
48
Cyclophosphamide Approved, Investigational Phase 1 50-18-0, 6055-19-2 2907
49
Sirolimus Approved, Investigational Phase 1 53123-88-9 5284616 6436030 46835353
50
Everolimus Approved Phase 1 159351-69-6 6442177 70789204

Interventional clinical trials:

(show all 42)
# Name Status NCT ID Phase Drugs
1 Analgesia of Fibula Free Flap Donor Site by Peri-Neuronal Catheter in Oro-Pharyngeal Carcinoma Surgery: Comparing Continuous Infusion of Local Anesthetic With Systemic Multimodal Analgesia Unknown status NCT00181038 Phase 3
2 DEPISTORL - THANCS (Trial of Head And Neck Cancer Screening) Randomized Multicenter Trial to Assess the Impact of a Screening Program for Heavy Alcohol Drinkers and Smokers Treated in Alcohol Addiction Clinics on Upper Aerodigestive Tract Cancer Mortality. Completed NCT00359645 Phase 3
3 A Phase III Randomized Trial of Docetaxel Based Induction Chemotherapy in Patients With N2/N3 Locally Advanced Head and Neck Cancer Completed NCT00117572 Phase 3 docetaxel;cisplatin;hydroxyurea;fluorouracil
4 Comparison of Salivary Interleukin-1β and Matrix Metalloproteinase-8 Levels in Individuals With Chronic Periodontitis Before and After Treatment With Nigella Sativa (Kalonji) Oil Unknown status NCT03270280 Phase 2 Nigella Sativa Oil;Normal saline
5 Combination of Cryosurgey and NK Immunotherapy for Recurrent Pharyngeal Cancer Completed NCT02849327 Phase 1, Phase 2
6 Phase 2 Study of Inductive Plus Concurrent Chemoradiation Versus Concurrent Plus Adjuvant Chemoradiation for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT Completed NCT01797900 Phase 2 Cisplatin;Paclitaxel
7 Larynx Preservation With Induction Chemotherapy (Cisplatin, 5FU, Docetaxel) Followed by Radiotherapy Combined With Either Cisplatin or Cetuximab in Laryngopharyngeal Squamous Cell Carcinoma - A Randomised Phase II Study Completed NCT00169247 Phase 2 cetuximab;Cisplatin
8 A Prospective Phase II Study of Involved Field Elective Volume De-Intensification for Oropharyngeal and Laryngeal Squamous Cell Carcinoma Treated With Intensity Modulated Radiation Therapy Completed NCT03067610 Phase 2 chemotherapy
9 Phase II Study of Concomitant Fluorouracil, Hydroxyurea, Cetuximab and Hyperfractionated Intensity Modulated Radiation Therapy for Locally Advanced Head and Neck Cancer Completed NCT00462735 Phase 2 Cetuximab;Hydroxyurea;Fluorouracil
10 Resistance Training During Radiation Therapy for Pharyngeal or Laryngeal Cancer Completed NCT00827164 Phase 2
11 Phase I/II Dose Escalation Trial of Induction and Concomitant Erlotinib and Celecoxib With Radiation Therapy for Treatment of Poor Prognosis Head and Neck Cancer, Including Reirradiation Completed NCT00970502 Phase 1, Phase 2 erlotinib + celecoxib
12 Dual Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Salivary Gland Cancers Recruiting NCT03749460 Phase 1, Phase 2
13 An Open-Label Phase 1B/2 Study to Evaluate the Safety and Efficacy of Tabelecleucel in Combination With Pembrolizumab in Subjects With Platinum-pretreated, Recurrent/Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma Recruiting NCT03769467 Phase 1, Phase 2
14 Phase II Randomized Trial Comparing Paclitaxel Combined With DDP Plus Concurrent Chemoradiotherapy With DDP Plus Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Active, not recruiting NCT03047265 Phase 2 Paclitaxel;Cisplatin
15 Phase II Study of Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma Terminated NCT00484601 Phase 2 Ifosfamide;Doxorubicin
16 Multiinstitutional Open Label Randomized Phase II Study Comparing Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy as Firstline Treatment for Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-NHSCC) Terminated NCT01216020 Phase 2 cetuximab;cisplatin (associated to radiotherapy)
17 Voice Prosthesis Made in Porous Titanium After Total Laryngectomy or Pharyngolaryngectomy Unknown status NCT00396617 Phase 1
18 Resistance Training and Physical Functioning in Head and Neck Cancer Patients Completed NCT01332682 Phase 1
19 Phase I Study of Bortezomib and Cetuximab Without or With Cisplatin in Combination With Radiation Therapy for Advanced Head and Neck Cancer Completed NCT01445405 Phase 1 Bortezomib (Velcade, PS-341);Cetuximab;Cisplatin
20 Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults Recruiting NCT03420963 Phase 1 Cyclophosphamide;Etoposide
21 A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other Indications Recruiting NCT01552434 Phase 1 Temsirolimus;Valproic Acid
22 Study of Previously Collected Blood and Tissue Samples From Patients With Nasopharyngeal Carcinoma,Laryngeal Carcinoma and Hypopharyngeal Carcinoma Unknown status NCT01171235
23 Morphological and Molecular Characterization of Tumors of the Aero-digestive Tract in Patients Who Have no Risk Factors Such as Alcohol, Smoking, or Occupation Unknown status NCT00963326
24 Technical Development of P16-INk4A-expressing Circulating Tumor Cells Detection Comparing With Human Papillomavirus Infection in Cancer Tissue in Patients With Head and Neck Cancer and Its Clinical Relevance. Unknown status NCT02791607
25 Pilot Study to Improve Therapeutic Outcomes for Dysphagia After Radiation Therapy Completed NCT02564887
26 Concurrent Angiogenic and EGFR Blockade in Conjunction With Curative Intent Chemoradiation for Locally Advanced Head and Neck Cancer Completed NCT00140556 Early Phase 1 Cisplatin;Bevacizumab;Erlotinib
27 A Speech Disorders Severity Index to Measure the Impact of Oral and Pharyngeal Cavity on Speech Production Completed NCT02875795
28 Natural History of Oral Cancer Precursors Completed NCT00179361
29 Exploration of the Diagnostic Capabilities of Ultrasound of the Oropharynx and Larynx Completed NCT00001167
30 A Randomized Longitudinal Intervention Study to Assess Whether Electronic Messaging Can Increase HPV Vaccine Utilization and Adherence Among College Students in Eastern North Carolina. Completed NCT01568515 Early Phase 1
31 Acupuncture Effect on Digestion in Critically Ill Post-Operative Oral and Hypo-pharyngeal Cancer Patients: A Protocol for Double Blind Randomized Control Trial Recruiting NCT03934294 Metoclopramide 10mg
32 Screening for Cancers in the Oral CAvity Targeting Tobacco Users in Somme, France Recruiting NCT01958762
33 Sammenligning Mellem Standard Tube og Den Ultra-tynde Tritube® Til Intubation, og Til Opretholdelse af Adgang Til Trachea Efter anæstesi, Hos Patienter Med Forventet Vanskelig Direkte Laryngoskopi Recruiting NCT03653039
34 Evaluation for NIDCD Head & Neck Surgery Branch Clinical Research Protocols Recruiting NCT00011492
35 Correlative Study of Nicotine Levels With Response Rates to Therapy Using Radiation Alone or in Combination With Chemotherapy in Head and Neck Cancer Recruiting NCT01084733
36 Biospecimen Procurement for NIDCD Clinical Protocols Recruiting NCT03429036
37 Quality of Life After Primary Transoral Robotic Surgery vs Intensity-modulated Radiotherapy for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma: A Randomized National Trial Recruiting NCT04124198 Cisplatin;Nimorazole.
38 A Matched Case Clinical Registry - Efficacy of AmnioFix in the Prevention of Post-Operative Salivary Leaks Following Head and Neck Surgery Enrolling by invitation NCT03479463
39 The Master Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT) Not yet recruiting NCT04028479 Treatment: CAR-T
40 Sentinel Node Localization in Larynx and Pharynx Cancers After Flexible Endoscopy-guided Tracer Injection: a Feasibility Study. Not yet recruiting NCT04068636
41 Assessment of Anti-cancerous Effect of Green, Roasted and Decaffeinated Coffee on Oral Squamous Cell Carcinoma Cell Line Not yet recruiting NCT03619304
42 Oropharyngeal Function After Radiotherapy With IMRT Terminated NCT00506324

Search NIH Clinical Center for Pharynx Cancer

Cochrane evidence based reviews: pharyngeal neoplasms

Genetic Tests for Pharynx Cancer

Anatomical Context for Pharynx Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Pharynx Cancer:

19
Pharynx

MalaCards organs/tissues related to Pharynx Cancer:

40
Thyroid, Liver, Bone, Salivary Gland, Lung, Heart, Breast

Publications for Pharynx Cancer

Articles related to Pharynx Cancer:

(show top 50) (show all 134)
# Title Authors PMID Year
1
A spatial study of oral & pharynx cancer mortality and incidence in the U.S.A.: 2000-2015. 61
32019034 2020
2
Alcohol-based mouthwash as a risk factor of oral cancer: A systematic review. 61
31655832 2020
3
Oral squamous cell cancer in a patient with Lynch syndrome. 61
31445773 2019
4
Potential years of life lost due to oropharyngeal cancer in Brazil: 1979 to 2013. 61
31483007 2019
5
Synchronous resection of esophageal cancer and other organ malignancies: A systematic review. 61
31341367 2019
6
Projecting Cancer Incidence for 2025 in the 2 Largest Populated Cities in Vietnam. 61
31331188 2019
7
Variation in Nordic Work-Related Cancer Risks after Adjustment for Alcohol and Tobacco. 61
30563223 2018
8
A Nationwide Cohort Study on the risk of non-gynecological cancers in women with surgically verified endometriosis. 61
29981163 2018
9
Oral and pharyngeal cancer risk associated with occupational carcinogenic substances: Systematic review. 61
30387891 2018
10
Diabetes in midlife and risk of cancer in late life: A nationwide Swedish twin study. 61
29566433 2018
11
Describing the association between socioeconomic inequalities and cancer survival: methodological guidelines and illustration with population-based data. 61
29844706 2018
12
[Gastrostomy tubes: indications and infectious complications in a tertiary hospital]. 61
28803460 2017
13
Association between Mediterranean diet and head and neck cancer: results of a large case-control study in Italy. 61
27483412 2017
14
Distribution of Cancer by Sex and Site in Nepal 61
28670003 2017
15
Extensions to Multivariate Space Time Mixture Modeling of Small Area Cancer Data. 61
28486417 2017
16
Head and Neck Cancers in North-East Iran: A 25 year Survey. 61
28589107 2017
17
Burden of cancer attributable to tobacco smoking in member countries of the Association of Southeast Asian Nations (ASEAN), 2012. 61
27513722 2016
18
Glottic Cancer: A Metamorphosing Disease. 61
26611243 2016
19
[Function sparing surgery for pharyngeal neoplasms]. 61
26897762 2015
20
An Ecological Analysis of Tobacco Use and Oral Cavity and Pharynx Cancers in U.S. Males. 61
26817067 2015
21
NUTRITIONAL, MICROBIOLOGICAL, AND THERAPEUTIC FACTORS RELATED TO MUCOSITIS IN HEAD AND NECK CANCER PATIENTS: A COHORT STUDY. 61
26319840 2015
22
Trend Analysis of Cancer Mortality and Incidence in Panama, Using Joinpoint Regression Analysis. 61
26091467 2015
23
[Multivariate analysis of pharyngo cutaneou fistulas after larynx cancer and lower pharynx cancer surgery]. 61
26201177 2015
24
Functional outcomes after TORS for oropharyngeal cancer: a systematic review. 61
24643851 2015
25
miR-494 represses HOXA10 expression and inhibits cell proliferation in oral cancer. 61
25500095 2015
26
[Oral cavity and pharynx cancer in the region of Siberia and Far East]. 61
26978750 2015
27
Inaccuracies in oral cavity-pharynx cancer coded as the underlying cause of death on U.S. death certificates, and trends in mortality rates (1999-2010). 61
24862544 2014
28
Spatial relationship quantification between environmental, socioeconomic and health data at different geographic levels. 61
24705362 2014
29
Adult height and head and neck cancer: a pooled analysis within the INHANCE Consortium. 61
24271556 2014
30
Incidence of oral cavity and pharyngeal cancers by anatomical sites in population-based registries in Puerto Rico and the United States of America. 61
24397214 2013
31
Chernobyl cleanup workers from Estonia: follow-up for cancer incidence and mortality. 61
23532116 2013
32
Genetic variations in XRCC1 gene in sporadic head and neck cancer (HNC) patients. 61
23055018 2013
33
Mortality rate of lip, oral cavity and pharynx malignant tumors in Serbia within a period 1991-2009. 61
23607187 2013
34
[Working conditions and mortality among men of working age in Russia (experience of Murmansk region)]. 61
24624870 2013
35
Differences in incidence rates and early detection of cancer among non-Hispanic and Hispanic Whites in the United States. 61
23914422 2013
36
Vitamin or mineral supplement intake and the risk of head and neck cancer: pooled analysis in the INHANCE consortium. 61
22173631 2012
37
Cancer incidence among workers exposed to softwood dust in Lithuania. 61
22241843 2012
38
The impact of lower induction values of 50 Hz external electromagnetic fields on in vitro T lymphocyte adherence capabilities. 61
22268989 2012
39
TALK score: Development and validation of a prognostic model for predicting larynx preservation outcome. 61
22374653 2012
40
Impact of delay in diagnosis on survival to head and neck carcinomas: a systematic review with meta-analysis. 61
22429704 2012
41
[Elements of completeness and results of the first year of registration of the "Registre général des cancers de Lille et de sa région"]. 61
22424751 2012
42
Oral cavity and pharynx cancer incidence trends by subsite in the United States: changing gender patterns. 61
22577381 2012
43
Incidence of oral cavity and pharynx cancer in New Hampshire, 1990-2007. 61
23493023 2012
44
HIV infection, immunodeficiency, viral replication, and the risk of cancer. 61
22109347 2011
45
Overexpression of TWIST2 correlates with poor prognosis in head and neck squamous cell carcinomas. 61
22201613 2011
46
US mortality rates for oral cavity and pharyngeal cancer by educational attainment. 61
22106232 2011
47
Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan. 61
21543188 2011
48
Comparison of time trends in lip, oral cavity and pharynx cancer mortality (1990-2006) between countries based on the WHO mortality database. 61
20978186 2010
49
Cancer incidence among women flax textile manufacturing workers in Lithuania. 61
20581260 2010
50
Body mass index, cigarette smoking, and alcohol consumption and cancers of the oral cavity, pharynx, and larynx: modeling odds ratios in pooled case-control data. 61
20494999 2010

Variations for Pharynx Cancer

Expression for Pharynx Cancer

Search GEO for disease gene expression data for Pharynx Cancer.

Pathways for Pharynx Cancer

Pathways related to Pharynx Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.93 MIR9-1 MIR34C MIR324 MIR30A MIR29C MIR29B1
2 11.36 MIR34C MIR30A MIR17
3 10.96 MIR93 MIR34C MIR27A MIR145
4 10.78 MIR34C MIR29C MIR29B1
5 10.44 MIR199A1 MIR145

GO Terms for Pharynx Cancer

Cellular components related to Pharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.4 MIR93 MIR30A MIR29C MIR29B1 MIR27A MIR21

Biological processes related to Pharynx Cancer according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.8 MIR125A MIR17 MIR185 MIR21 MIR27A MIR29B1
2 negative regulation of cell migration GO:0030336 9.78 MIR21 MIR29B1 MIR29C MIR9-1
3 negative regulation of protein kinase B signaling GO:0051898 9.73 MIR145 MIR29B1 MIR29C MIR34C
4 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.72 MIR21 MIR29B1 MIR29C
5 negative regulation of angiogenesis GO:0016525 9.72 MIR125A MIR145 MIR185 MIR21 MIR29C
6 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.69 MIR17 MIR21 MIR27A
7 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.63 MIR145 MIR199A1 MIR21
8 positive regulation of vascular endothelial cell proliferation GO:1905564 9.61 MIR21 MIR27A
9 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.6 MIR10B MIR27A
10 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.59 MIR17 MIR21
11 negative regulation of cardiac muscle hypertrophy GO:0010614 9.58 MIR145 MIR21
12 regulation of DNA methylation GO:0044030 9.58 MIR29B1 MIR29C
13 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.58 MIR17 MIR199A1 MIR34C
14 positive regulation of connective tissue replacement GO:1905205 9.57 MIR199A1 MIR34C
15 positive regulation of mitochondrial membrane permeability involved in apoptotic process GO:1902110 9.56 MIR29B1 MIR29C
16 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.54 MIR17 MIR21
17 positive regulation of metalloendopeptidase activity GO:1904685 9.54 MIR17 MIR21 MIR29B1
18 negative regulation of low-density lipoprotein receptor activity GO:1905598 9.52 MIR185 MIR27A
19 miRNA mediated inhibition of translation GO:0035278 9.5 MIR145 MIR17 MIR21 MIR27A MIR29B1 MIR30A
20 gene silencing by miRNA GO:0035195 9.5 MIR93 MIR9-1 MIR34C MIR30A MIR29C MIR29B1
21 negative regulation of circulating fibrinogen levels GO:0061754 9.49 MIR29B1 MIR29C
22 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.46 MIR17 MIR185 MIR199A1 MIR27A

Molecular functions related to Pharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.47 MIR93 MIR9-1 MIR30A MIR29C MIR29B1 MIR27A

Sources for Pharynx Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....